Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516540 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2TP53RXFP1GRM5 | |
| SCHEMBL6510975 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2TP53RXFP1GRM5 | |
| SCHEMBL6516507 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL6513343 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL6521236 | 0.88 | TRPV1 (0.48) | LMNASMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL12604462 | 0.88 | LMNA (0.54) | LMNASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL6518322 | 0.87 | RAF1 (0.48) | LMNASMN1; SMN2TP53GRM5MAPT | |
| SCHEMBL6515209 | 0.87 | AAK1 (0.45) | LMNAGRM5MAPTHTTKMT2A | |
| SCHEMBL6518314 | 0.87 | RAF1 (0.48) | LMNASMN1; SMN2TP53GRM5MAPT | |
| SCHEMBL6515200 | 0.87 | AAK1 (0.45) | LMNAGRM5MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148643-A1 | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | claimed |
| US-20050148643-A1 | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148643-A1 | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme | CHEK1, CHEK2, RAD1 | LMNA 2123/4885SMN1; SMN2 2438/4885TP53 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.